Skip to main content
SpringerLink
Log in

Arthritis, Arthropathy, and Osteoporosis in Inflammatory Bowel Disease

  • Chapter
  • First Online:
Crohn's Disease and Ulcerative Colitis

  • 3490 Accesses

Abstract

The most common extraintestinal manifestation in inflammatory bowel disease (IBD) is musculoskeletal disease. Arthritis associated with IBD is distinct from rheumatoid arthritis and is classified with an extended disease group, namely the spondyloarthropathies (SpA). The spondyloarthropathies share common pathophysiology, clinical manifestations, and approaches to investigation and management. Remarkably, they also provide for evolution of the clinical phenotype across tissue compartments, e.g., an IBD dominant presentation may evolve to include significant musculoskeletal or ocular involvement. Such disease developments may impose substantial novel impact on quality of life and require an altered management approach and prioritization. Indeed they may become the dominant clinical issue over time, transiently or in perpetuity. Cross-disciplinary recognition of the propensity for a developing presentation and management of disease evolution is therefore essential. Herein we summarize the key elements of the musculoskeletal elements required for the management of IBD and its wider disease spectrum.

From the Arthritis Research UK Centre of Excellence for Rheumatoid Arthritis Pathogenesis (RACE).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Levine JS, Burakoff R. Extraintestinal Manifestations of Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2011;7(4):235–41.

    Google Scholar 

  2. Huang V, Mishra R, Thanabalan R, Nguyen GC. Patient awareness of extraintestinal manifestations of inflammatory bowel disease. J Crohns Colitis. 2013;7(8):e318–24.

    Article  PubMed  Google Scholar 

  3. Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics and non-Hispanic Whites: characterisation of a large North American cohort. Am J Gastroenterol. 2006;101(5):1012–23.

    Article  PubMed  Google Scholar 

  4. Ott C, Takses A, Obermeier F, Schnoy E, Muller M. Smoking increases the risk of extraintestinal manifestations in Crohn’s disease. World J Gastroenterol. 2014;20(34):12269–76.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Voulgari PV. Rheumatological manifestations in inflammatory bowel disease. Ann Gastroenterol. 2011;24(3):173–80.

    PubMed  PubMed Central  Google Scholar 

  6. Reveille JD. Genetics of spondyloarthritis—beyond the MHC. Nat Rev Rheumatol. 2012;8(5):296–304.

    Article  CAS  PubMed  Google Scholar 

  7. Bowes J, Budu-Aggrey A, Huffmeier U, Uebe S, Steel K, Hebert HL, et al. Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nat Commun. 2015;6:6046.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Cortes A, Pulit SL, Leo PJ, Pointon JJ, Robinson PC, Weisman MH, et al. Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nat Commun. 2015;6:7146.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Asquith M, Elewaut D, Lin P, Rosenbaum JT, et al. The role of the gut and microbes in the pathogenesis of spondyloarthritis. Best Pract Res Clin Rheumatol. 2014;28(5):687–702.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Scher JU, Littman DR, Abramson SB. Microbiome in inflammatory arthritis and human rheumatic diseases. Arthritis Rheumatol. 2015 Sep 2.

    Google Scholar 

  11. Jacques P, McGonagle D. The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it. Best Pract Res Clin Rheumatol. 2014;28(5):703–10.

    Article  PubMed  Google Scholar 

  12. McGonagle DG, Helliwell P, Veale D. Enthesitis in psoriatic disease. Dermatology. 2012;225(2):100–9.

    Article  PubMed  Google Scholar 

  13. Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44(2):183–93.

    Article  CAS  PubMed  Google Scholar 

  14. Palmer MT, Weaver CT. Immunology: narcissistic helpers. Nature. 2007;448(7152):416–8.

    Article  CAS  PubMed  Google Scholar 

  15. Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008;58(8):2307–17.

    Article  PubMed  Google Scholar 

  16. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt + CD3 + CD4 − CD8− entheseal resident T cells. Nat Med. 2012;18(7):1069–76.

    Article  CAS  PubMed  Google Scholar 

  17. Smith JA, Colbert RA. The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol. 2014;66(2):231–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888–98.

    Article  CAS  PubMed  Google Scholar 

  19. Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160(2):319–24.

    Article  CAS  PubMed  Google Scholar 

  20. McGonagle D, Benjamin M. Entheses, enthesitis and enthesopathy. Arthritis Research UK Topical Reviews. 2009 Autumn, issue 4, series 6.

    Google Scholar 

  21. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60(6):1647–56.

    Article  CAS  PubMed  Google Scholar 

  22. Menon B, Gullick NJ, Walter GJ, Rajasekhar M, Garrood T, Evans HG, et al. Interleukin-17 + CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014;66(5):1272–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther. 2011;13(3):R95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Braun J, Klitz U, Heldmann F, Baraliakos X. Emerging drugs for the treatment of axial and peripheral spondyloarthritis. Expert Opin Emerg Drugs. 2015;20(1):1–14.

    Article  CAS  PubMed  Google Scholar 

  25. Lories RJ, Schett G. Pathophysiology of new bone formation and ankyloses in spondyloarthritis. Rheum Dis Clin North Am. 2012;38(3):555–67.

    Article  PubMed  Google Scholar 

  26. Moyssakis I, Gialafos E, Vassiliou VA, Boki K, Votteas V, Sfikakis PP, et al. Myocardial performance and aortic elasticity are impaired in patients with ankylosing spondylitis. Scand J Rheumatol. 2009;38(3):216–21.

    Article  CAS  PubMed  Google Scholar 

  27. Han C, Robinson Jr DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33(11):2167–72.

    PubMed  Google Scholar 

  28. Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systemic review. Ann Rheum Dis. 2013;72(2):211–6.

    Article  PubMed  Google Scholar 

  29. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045–50.

    Article  CAS  PubMed  Google Scholar 

  30. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–83.

    Article  CAS  PubMed  Google Scholar 

  31. Kiltz U, van der Heijde D, Boonen A, Braun J. The ASAS Health Index (ASAS HI)—a new tool to assess the health status of patients with spondyloarthritis. Clin Exp Rheumatol. 2014;32 Suppl 85:S105–8.

    Google Scholar 

  32. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis. 2005;64 Suppl 2:ii49–54.

    PubMed  PubMed Central  Google Scholar 

  33. Mease P. Psoriatic arthritis and spondyloarthritis assessment and management update. Curr Opin Rheumatol. 2013;25(3):287–96.

    Article  CAS  PubMed  Google Scholar 

  34. Robinson PC, Bird P, Lim I, et al. Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA). Int J Rheum Dis. 2014;17(5):548–56.

    PubMed  Google Scholar 

  35. Paramrta JE, Baeten D. Spondyloarthritis: from unifying concepts to improved treatment. Rheumatology (Oxford). 2014;53(9):1547–59.

    Article  Google Scholar 

  36. Ficjan A, Husic R, Gretler J, Lackner A, Graninger WB, Gutierrez M, et al. Ultrasound composite scores for the assessment of inflammatory and structural pathologies in Psoriatic Arthritis (PsASon-Score). Arthritis Res Ther. 2014;16(5):476.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Rudwaleit M, Sieper J. Referral strategies for early diagnosis of axial spondyloarthritis. Nat Rev Rheumatol. 2012;8(5):262–8.

    Article  CAS  PubMed  Google Scholar 

  38. Raychaudhuri SP, Deodhar AJ. The classification and diagnostic criteria of ankylosing spondylitis. J Autoimmun. 2014;48–49:128–33.

    Article  PubMed  Google Scholar 

  39. Peluso R, Manguso F, Vitiello M, Iervolino S, Di Minno MN. Management of arthropathy in inflammatory bowel diseases. Ther Adv Chronic Dis. 2015;6(2):65–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Zochling J, Braun J. Remission in ankylosing spondylitis. Clin Exp Rheumatol. 2006;24 Suppl 43:S88–92.

    Google Scholar 

  41. Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014;73(1):101–7.

    Article  CAS  PubMed  Google Scholar 

  42. Sieper J, Lenaerts J, Wollenhaupt J, et al. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis,: results from a 6-month, randomised, open-label follow-up study, INFAST, Part 2. Ann Rheum Dis. 2014;73(1):108–13.

    Article  CAS  PubMed  Google Scholar 

  43. Baraliakos X, Listing J, Brandt J, Rudwaleit M, Sieper J, Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7:R439–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Van der Heijde D, Landewe R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58(10):3063–70.

    Article  PubMed  Google Scholar 

  45. Van der Heijde D, Landewe R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58(5):1324–31.

    Article  PubMed  Google Scholar 

  46. McInnes IB, Kavanaugh A, Gottlieb ABM, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780–9.

    Article  CAS  PubMed  Google Scholar 

  47. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, You Y, Wang Y, et al. OP0174 efficacy and safety of ustekinumab in psoriatic arthritis patients with spondylitis and peripheral joint involvement: results from a phase 3, multicenter, double-blind, placebo-controlled study. Ann Rheum Dis. 2015;74:136. doi:10.1136/annrheumdis-2015-eular.3096.

    Article  Google Scholar 

  49. Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73:1000–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Baetan D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705–13.

    Article  Google Scholar 

  51. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; Epub ahead of print. doi: 10.1016/S0140-6736(15)61134-5.

  52. van der Heijde D, Landewé R, Mease P, McInnes IB, Conaghan PG, Pricop L, et al. THU0414 secukinumab inhibits radiographic progression in patients with psoriatic arthritis: data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study (Future 1). Ann Rheum Dis. 2015;74:347–8. doi:10.1136/annrheumdis-2015-eular.1806.

    Article  Google Scholar 

  53. Edwards C, Blanco F, Crowley J, Hu C, Shah K, Birbara C. THU0416 disease activity and safety during long-term (104-week) treatment with apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase III, randomized, controlled trial and open-label extension (Palace 3). Ann Rheum Dis. 2015;74 Suppl 2:348–9. doi:10.1136/annrheumdis-2015-eular.2889.

    Google Scholar 

  54. Kavanaugh A, Adebajo A, Gladman D, Gomez-Reino J, Hall S, Lespessailles E, et al. THU0420 long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase III, randomised, controlled trial and open-label extension (Palace 1). Ann Rheum Dis. 2015;74 Suppl 2:350–1. doi:10.1136/annrheumdis-2015-eular.2907.

    Google Scholar 

  55. Coates L, Moverley A, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a multicentre, open-label, randomised controlled trial. Lancet. 2014;383:S36.

    Article  Google Scholar 

  56. Coates L, Navarro-Coy N, Brown S, et al. The TICOPA protocol (TIghtCOntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord. 2013;14:101.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Targownik LE, Bernstein CN, Leslie WD. Risk factors and management of osteoporosis in inflammatory bowel disease. Curr Opin Gastroenterol. 2014;30(2):168–74.

    Article  PubMed  Google Scholar 

  58. Scottish Intercollegiate Guidelines Network (SIGN). Management of osteoporosis and the prevention of fragility fractures. Edinburgh: SIGN; 2015. (SIGN publication no. 142). [March 2015]. Available from URL: http://www.sign.ac.uk.

Download references

Author information

Authors and Affiliations

  1. Institute of Infection, Immunity and Inflammation, College of MVLS, University of Glasgow, 120 University Place, Glasgow, G128QQ, UK

    Alistair Tindell, Hanna Johnsson & Iain B. McInnes

Authors
  1. Alistair Tindell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanna Johnsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Iain B. McInnes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Iain B. McInnes .

Editor information

Editors and Affiliations

  1. Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Charité Medical School—Humboldt-University of Berlin, Berlin, Germany

    Daniel C. Baumgart

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Tindell, A., Johnsson, H., McInnes, I.B. (2017). Arthritis, Arthropathy, and Osteoporosis in Inflammatory Bowel Disease. In: Baumgart, D. (eds) Crohn's Disease and Ulcerative Colitis. Springer, Cham. https://doi.org/10.1007/978-3-319-33703-6_55

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33703-6_55

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33701-2

  • Online ISBN: 978-3-319-33703-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation